Eli Lilly and Company's amyloid-beta antibody donanemab for Alzheimer's disease could be a near-term blockbuster commercial opportunity. So, unsurprisingly, the pipeline candidate overshadowed the company's second quarter financial results on 3 August.
Lilly Is Revved Up About Alzheimer's Opportunity
The upcoming filing of Lilly's Alzheimer's antibody donanemab dominated the company's second quarter call. Lilly is also developing a new blood test to confirm diagnosis and a second-generation antibody.
